To examine the relationship between specific osteoporosis therapies, such as bisphosphonates and denosumab, and their effects on coronary biology and cardiovascular risk, particularly focusing on vascular calcification and sclerostin pathways.
Key Findings:
Osteoporosis therapies, particularly bisphosphonates and denosumab, show biological relevance to vascular calcification but lack consistent evidence for significant effects on coronary-specific outcomes, highlighting the need for further research.
Romosozumab presents a unique case with strong anti-fracture efficacy but unresolved cardiovascular safety concerns related to sclerostin inhibition, necessitating cautious interpretation.
Current studies indicate a drug-specific and context-dependent relationship between osteoporosis treatments and cardiovascular outcomes, rather than a uniform class effect, underscoring the complexity of these interactions.
Interpretation:
The interplay between osteoporosis and coronary artery disease suggests a complex relationship influenced by various biological pathways, but the clinical implications of osteoporosis therapies on cardiovascular health remain unclear and inconsistent, warranting further investigation.
Limitations:
Heterogeneity in vascular endpoints and the distinction between calcification burden and plaque vulnerability complicate the interpretation of results, particularly in diverse populations.
Current studies often do not provide clear evidence linking osteoporosis treatments to coronary-specific outcomes, limiting the ability to draw definitive conclusions.
Population-specific factors and the limitations of fracture trials hinder the ability to draw definitive conclusions, emphasizing the need for tailored research.
Conclusion:
The evidence does not support a uniform cardiovascular effect of osteoporosis therapies; rather, their vascular consequences are highly specific to the drug, patient phenotype, and clinical context, which should inform clinical decision-making.
